ReproCELL Incorporated (TYO:4978)
181.00
+3.00 (1.69%)
Aug 29, 2025, 1:43 PM JST
ReproCELL Revenue
ReproCELL had revenue of 475.00M JPY in the quarter ending June 30, 2025, a decrease of -23.26%. This brings the company's revenue in the last twelve months to 2.83B, up 13.86% year-over-year. In the fiscal year ending March 31, 2025, ReproCELL had annual revenue of 2.98B with 22.75% growth.
Revenue (ttm)
2.83B
Revenue Growth
+13.86%
P/S Ratio
5.95
Revenue / Employee
28.63M
Employees
99
Market Cap
16.85B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 2.98B | 552.00M | 22.75% |
Mar 31, 2024 | 2.43B | -527.00M | -17.85% |
Mar 31, 2023 | 2.95B | 719.00M | 32.18% |
Mar 31, 2022 | 2.23B | 948.00M | 73.72% |
Mar 31, 2021 | 1.29B | 87.00M | 7.26% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.21B |
Takeda Pharmaceutical Company | 4,480.25B |
Daiichi Sankyo Company | 1,924.68B |
HOYA Corporation | 876.09B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |